Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Frost & Sullivan Study Reveals the CRAMS Market in India to be Valued at US $895 Million in 2006 and Expected to Reach to Close to US $6.6 Billion by

Abstract:
As per a Frost & Sullivan study, the Contract Research and Manufacturing Services (CRAMS) industry in India is estimated to have earned revenues of approximately US $895 million in the year 2006. The momentum gained by this segment of the Indian Pharmaceutical Industry is worth noting. Over the last 5 years the CRAMS industry has been contributing close to 8 percent to the total Indian pharmaceutical business. Factors like a vast expanse of specialty hospitals with state-of-the-art facilities (nearly 700,000 hospital beds and 221 medical colleges); large English speaking population and rich talent pool; diverse population - large and diverse gene pool; increasing number of chronic diseases and a combination of diseases characteristic of developing and the developed countries is expected to propel the CRAMS industry to grow at a CAGR of nearly 32 percent from 2006 to 2013.

Frost & Sullivan Study Reveals the CRAMS Market in India to be Valued at US $895 Million in 2006 and Expected to Reach to Close to US $6.6 Billion by

Mumbai, Maharashtra, India | Posted on April 23rd, 2007

Frost & Sullivan is set to release the study titled ‘The Indian Contract Research and Manufacturing Services market' during the CRAMS SUMMIT 2007 - Emerging Opportunities and Business Models to be held on 27th April 2007 at the JW Marriott Hotel, Mumbai. The report offers coverage on the composition of the CRAMS market and its value chain components. Additionally, it highlights the factors propelling the growth of this market in India, which is slated to be a driver for the Indian pharmaceutical and life sciences industry. The study looks at the market composition, growth, drivers and restraints, challenges and regulatory aspects that affect each of the value chain components and is based on the industry knowledge collected through discussions with the key industry players and published information.

The coveted event will focus on the emerging opportunities and business models in the much talked about Contract Research and Manufacturing Services industry in India. The CRAMS SUMMIT agenda is divided into 3 sessions. The first session will have Mr. Venkat Jasti, CEO, Suven Life Sciences speaking about the collaborative research partnerships in drug discovery. Dr. David Cavalla, CEO, Myotek UK will share his experiences of Reprofiling of drug candidates for different therapeutic uses. The session ends with Mr. Ajit Mahadevan, President, Pharma Formulations at NPIL sharing highlights on the Mergers and acquisition trends in the Contract Manufacturing market.

The second session is more focused on the technology advancements that can be utilized in the Contract Research area. Dr. Lalit Bharadwaj, Deputy Director, CSIR will talk about the usage of nanotechnology and its applications, while Dr. Sudhir Borgonha, CEO, Molecular Research Services India Pvt. Ltd. will discuss the use of biomarkers and translational medicine in clinical research.

The post lunch session will have an interactive workshop conducted by Dr. Joachim Greuel, Partner, BioScience Valuation BSV GmbH on the ‘Analysis and Valuation of In-licensing Opportunities.'

According to Mahesh Sawant, Program Manager, Healthcare Practice, Frost & Sullivan, "The Indian Life Sciences industry is transitioning towards newer business models such as CRAMS. The CRAMS model is slowly moving up the value chain with focus now shifting towards providing services in areas within contract research and manufacturing, which were traditionally not looked at. The CRAMS Summit 2007 will help in providing inputs into these emerging areas and business models."

CRAMS SUMMIT 2007 is a gathering of experts and leaders from the Indian and global life sciences industry. The conference will serve as a conclave of thought leaders and offer insights into their learning's and also as an ideal platform for networking and initiation of business partnerships. With international participation expected from leading pharmaceutical companies and contract service providers this summit could be an arena for knowledge exchange in the areas of R&D, strategic partnership and outsourcing, emerging technologies in drug manufacturing, custom synthesis, clinical research, marketing and distribution, global leadership, and many more. The one day conference will culminate into the ‘Partner of Choice Awards 2007'.

‘The Partner of Choice Awards 2007' organized by Frost & Sullivan, recognizes the best Indian Research and Manufacturing Services Capability in Life Sciences and assesses its Global Competitiveness. These awards acknowledge the best life science facilities in India that have achieved and sustained excellence in their industry value chain component. The facilities that are commended as award winners are those with the diligence, perseverance, foresight and dedication required to develop a successful organization and sustain continuous learning to be the true Partners of Choice.

####

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 45 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com .

For more information, please click here

Contacts:
Nimisha Iyer, Corporate Communications,
Frost & Sullivan,
+91 (022) 4001 3404,


Shwetha Thomas, Corporate Communications,
Frost & Sullivan,
+91 (022) 4001 3429,

Copyright © Business Wire India

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

Leti Will Demonstrate First 3D Anti-Crash Solution for Embedding in Drones: Fitted on a Mass-Market Microcontroller, 360Fusion Software Technology Detects any Dynamic Obstacle and Helps Guide Drones Away from Collisions December 15th, 2017

Synthetic protein packages its own genetic material and evolves computationally designed protein assemblies are advancing research in synthetic life and in targeted drug delivery December 15th, 2017

A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

Synthetic protein packages its own genetic material and evolves computationally designed protein assemblies are advancing research in synthetic life and in targeted drug delivery December 15th, 2017

UCLA chemists synthesize narrow ribbons of graphene using only light and heat: Tiny structures could be next-generation solution for smaller electronic devices December 8th, 2017

Device makes power conversion more efficient: New design could dramatically cut energy waste in electric vehicles, data centers, and the power grid December 8th, 2017

Creating a new kind of metallic glass December 7th, 2017

Events/Classes

Leti Will Demonstrate First 3D Anti-Crash Solution for Embedding in Drones: Fitted on a Mass-Market Microcontroller, 360Fusion Software Technology Detects any Dynamic Obstacle and Helps Guide Drones Away from Collisions December 15th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Leti Breakthroughs Point Way to Significant Improvements in SoC Memories December 6th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project